<?xml version='1.0' encoding='utf-8'?>
<document id="16356485"><sentence text="Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034." /><sentence text="CI-1034, an endothelin-A receptor antagonist was being developed for pulmonary hypertension" /><sentence text=" Drug-drug interaction studies using human hepatic microsomes were conducted to assess CYP1A2, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 inhibition potential; CYP3A4 induction potential was evaluated using primary human hepatocytes" /><sentence text=" CI-1034 moderately inhibited CYP2C9 (IC(50) 39" /><sentence text="6 microM) and CYP3A4 activity (IC(50) 21" /><sentence text="6 microM); CYP3A4 inhibition was metabolism-dependent" /><sentence text=" In human hepatocytes, no increase in CYP3A4 activity was observed in vitro, while mRNA was induced 15-fold, similar to rifampin, indicating that CI-1034 is both an inhibitor and inducer of CYP3A4"><entity charOffset="120-128" id="DDI-PubMed.16356485.s7.e0" text="rifampin" /></sentence><sentence text=" A 2-week clinical study was conducted to assess pharmacokinetics, pharmacodynamics and safety" /><sentence text=" No significant changes were observed in [formula: see text] between days 1 and 14" /><sentence text=" However, reversible elevations of serum liver enzymes were observed with a 50mg BID dose and the program was terminated" /><sentence text=" To further understand the interactions of CI-1034 in the liver and possible mechanisms of the observed hepatotoxicity, we evaluated the effect of CI-1034 on bile acid transport and previously reported that CI-1034 inhibited biliary efflux of taurocholate by 60%, in vitro"><entity charOffset="158-167" id="DDI-PubMed.16356485.s11.e0" text="bile acid" /><entity charOffset="243-255" id="DDI-PubMed.16356485.s11.e1" text="taurocholate" /><pair ddi="false" e1="DDI-PubMed.16356485.s11.e0" e2="DDI-PubMed.16356485.s11.e0" /><pair ddi="false" e1="DDI-PubMed.16356485.s11.e0" e2="DDI-PubMed.16356485.s11.e1" /></sentence><sentence text=" This indicated that inhibition of major hepatic transporters could be involved in the observed hepatotoxicity" /><sentence text=" We next evaluated the in vitro inhibition potential of CI-1034 with the major hepatic transporters OATP1B1, OATP1B3, OATP2B1, MDR1, MRP2 and OCT" /><sentence text=" CI-1034 inhibited OATP1B1 (K(i) 2 microM), OATP1B3 (K(i) 1" /><sentence text="8 microM) and OATP2B1 activity (K(i) 3" /><sentence text="3 microM) but not OCT, MDR1 or MRP2 mediated transport" /><sentence text=" Our data indicates that CI-1034 is an inhibitor of major hepatic transporters and inhibition of bile efflux may have contributed to the observed clinical hepatotoxicity" /><sentence text=" We recommend that in vitro drug-drug interaction panels include inhibition and induction studies with transporters and drug metabolizing enzymes, to more completely assess potential in vivo interactions or toxicity" /><sentence text="" /></document>